PLLA+HA Poly-L-Lactic Acid Microsphere Composite Gel（Soft-State Regenerative Composite Base Material）
Product Overview
This product is a medical biomaterial raw material compounded from Poly-L-Lactic Acid (PLLA) microspheres and high-purity Hyaluronic Acid (HA) gel. It is intended for downstream customers in the R&D of compounded light-medical-aesthetics repair and moisturizing finished products and their corresponding formulations. The system combines the gentle characteristics of PLLA with the instant hydration and support of HA, offering moderate degradation, a smooth and soft texture, and avoiding the dryness typical of single microsphere powders. As a semi-finished raw material, it is not for direct use on the human body and does not constitute a finished medical device or cosmetic product.
Core Customization Capabilities
Adjustable particle size: built-in PLLA microspheres support full-range customization from 10–100 μm, with 20–50 μm as the general-fit range for multi-level soft-tissue repair formulations;
Adjustable degradation period: degradation rate is regulated through the PLLA molecular structure to achieve medium-rate sustained release;
Adjustable compounding ratio: the PLLA-to-HA ratio can be customized on demand, and may also accommodate active ingredients such as recombinant collagen and PDRN to enrich the finished-product portfolio;
Optimized dispersion system: microspheres are uniformly dispersed in the HA gel, with no settling or agglomeration, eliminating the need for complex homogenization and simplifying downstream formulation processing;
Adjustable gel matrix: HA gel viscoelasticity and permeability can be tuned to suit different downstream application scenarios.
Mechanism of Action
Within the composite system, the HA gel quickly fills soft-tissue spaces, providing immediate hydration and a smooth application feel, while the PLLA microspheres undergo steady, gentle hydrolysis with low irritation. Together they form a synergistic "immediate + long-term" compound system. Actual biological performance depends on downstream finished-product formulations, processing techniques and clinical validation; no efficacy claims are made at the raw-material level.
Key Advantages
Synergistic soft-hard system: HA provides immediate hydration and support, while PLLA delivers long-term sustained repair, balancing short-term results and long-term maintenance;
Excellent biocompatibility: gentle degradation reactions, suitable for mid-face and shallow sensitive soft-tissue applications;
Flexible parameter customization: microsphere particle size, degradation period, solid content ratio and matrix viscosity are all adjustable, enabling one raw material to support multiple finished-product lines;
Strong compatibility: compatible with a wide range of bioactive ingredients, reducing formulation debugging and R&D trial costs for brands;
High-purity raw-material standard: production standard benchmarks implant-grade biomaterials, with physicochemical properties meeting medical-device raw-material compliance requirements.
Application Scenarios
Brand/OEM side: formulation development and OEM composite base materials for compounded repair and moisturizing finished products;
Supply-channel side: composite base raw materials supplied to downstream customers.
Quality and Compliance Statement
Our company only develops and sells medical biomaterial raw materials; we do not manufacture or sell finished medical devices. Customers are responsible for the R&D, processing and regulatory registration of finished products after purchasing raw materials, and finished products may only be marketed after obtaining the corresponding compliance qualifications. This document objectively describes only the physicochemical properties of the raw material and does not constitute any claim of efficacy for finished products.